A 62-year-old with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) was successfully treated with immunosuppressants and vasodilators, a case study…
Articles by Margarida Azevedo, MSc
The Phase 2 HELP study testing levosimendan as a potential treatment for pulmonary hypertension (PH) has exceeded…
The number of both new and existing cases of pulmonary arterial hypertension (PAH) in the southwestern U.S. population…
Aria CV announced the end of a funding round that will be used to finance a feasibility study of its…
A unique bacterial profile in the guts of patients with pulmonary arterial hypertension (PAH) may contribute to the disease…
Mast Therapeutics Inc. announced positive interim results from an ongoing Phase 2a clinical study of its investigational drug AIR001 for the treatment…
Bayer Pharmaceuticals announced it is terminating a Phase 2 clinical trial evaluating the efficacy and safety of riociguat in patients with pulmonary hypertension (PH)…
Insmed, Inc., recently announced that three abstracts related to Arikayce, its drug candidate to treat nontuberculous mycobacteria (NTM) lung disease, and…
The Pulmonary Hypertension Association (PHA) announced the launch of “PH Care for All,” an initiative to address disparities in the treatment…
Praxair, Inc., announced that it has received approval, through a subsidiary, for the sale of its Noxivent brand of inhaled nitric oxide…
Actelion has announced that its orally active pulmonary arterial hypertension (PAH) drug, Uptravi (selexipag), has been approved for the treatment of PAH…
Pulmonary hemodynamic response to exercise can predict the transplant-free survival chances of people with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension…